Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) is an investigational cell therapy being developed by Beijing 302 Hospital (also known as The Fifth Medical Center of Chinese PLA General Hospital) for the treatment of liver failure, including acute-on-chronic liver failure (ACLF) and decompensated liver cirrhosis. The therapy involves the intravenous infusion of allogeneic MSCs derived from the Wharton's jelly of human umbilical cords. These cells are expanded in vitro in GMP-compliant facilities and administered in multiple infusions. The mechanism of action is multifaceted, primarily involving immunomodulation and tissue regeneration. The cells suppress systemic inflammation by inhibiting pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17), and by modulating signaling pathways including JAK-STAT and PI3K-Akt. Clinical evaluations have demonstrated improvements in liver function and survival rates in patients with end-stage liver disease.
- Other names
- Wharton's jelly-derived mesenchymal stem cellsallogeneic human umbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital).